Enanta Pharma (ENTA) Misses Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- SpaceX slides, tech stocks dip — what’s moving markets
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
November 20, 2017 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Cash and marketable securities totaled $293.7 million at September 30, 2017 Total revenue for the quarter was $75.9 million Milestone payments totaling $65.0 million received following AbbVies U.S. approval of MAVYRET (glecaprevir/pibrentasvir) and EU approval of MAVIRET (glecaprevir/pibrentasvir) Positive Phase 1 results for EDP-305 support further clinical evaluation in PBC and NASH patients Fast Track designation granted to EDP-305 by the U.S. FDA for the treatment of patients with primary... More